The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11032 results:
[ Author(Asc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Polyzos, S. A., Kountouras J., Zavos C., Pyrrou N., & Tantsi N. (2013).  Helicobacter pylori infection and serum adiponectin.. Helicobacter. 18(4), 321-2.
Polyzos, S. A., Cundy T., & Mantzoros C. S. (2018).  Juvenile Paget disease.. Metabolism. 80, 15-26.
Polyzos, S. A., & Anastasilakis A. D. (2010).  Alterations in serum thyroid-related constituents after thyroid fine-needle biopsy: a systematic review.. Thyroid. 20(3), 265-71.
Polyzos, S. A., Nikolopoulos P., Stogianni A., Romiopoulos I., Katsinelos P., & Kountouras J. (2014).  Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study.. Arq Gastroenterol. 51(3), 261-8.
Polyzos, S. A., Anastasilakis A. D., Anagnostis P., Kita M., Arsos G., Moralidis E., et al. (2012).  Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.. Endokrynol Pol. 63(4), 312-5.
Polyzos, S. A., & Anastasilakis A. D. (2010).  Infectious thyroiditis as a complication of fine-needle biopsy: a systematic review.. Expert Rev Endocrinol Metab. 5(5), 673-679.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2015).  Leptin in nonalcoholic fatty liver disease: a narrative review.. Metabolism. 64(1), 60-78.
Polyzos, S. A., Kang E. Seok, Boutari C., Rhee E-J., & Mantzoros C. S. (2020).  Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.. Metabolism. 154203.
Polyzos, S. A., Kechagias S., & Tsochatzis E. A. (2021).  Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations.. Aliment Pharmacol Ther.
Polyzos, S. A., Kountouras J., & Zavos C. (2011).  Adiponectin in non-alcoholic fatty liver disease treatment: therapeutic perspectives and unresolved dilemmas.. Int J Clin Pract. 65(3), 373-4.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Margouta A., & Mantzoros C. S. (2015).  Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease.. Endocrine. 49(2), 560-2.
Polyzos, S. A., Makras P., Anastasilakis A. D., Mintziori G., Kita M., Papatheodorou A., et al. (2017).  Periostin and sclerostin levels in juvenile Paget's disease.. Clin Cases Miner Bone Metab. 14(2), 269-271.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Makras P., Hawa G., Sonnleitner L., et al. (2018).  Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.. Hormones (Athens). 17(4), 573-579.
Polyzos, S. A., Mousiolis A., Mintziori G., & Goulis D. G. (2020).  Nonalcoholic fatty liver disease in males with low testosterone concentrations.. Diabetes Metab Syndr. 14(5), 1571-1577.
Polyzos, S. A., & Katsiki N. (2022).  Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.. Hormones (Athens).
Polyzos, S. A., Kountouras J., Goulas A., Papakonstantinou E., & Papaioannidou P. (2020).  Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity.. Hepatobiliary Surg Nutr. 9(1), 73-76.
Polyzos, S. A., Tournis S., Goulas A., Kollia P., & Whyte M. P. (2021).  Adult hypophosphatasia treated with reduced frequency of teriparatide dosing.. J Musculoskelet Neuronal Interact. 21(4), 584-589.
Polyzos, S. A., Vachliotis I. D., & Mantzoros C. S. (2023).  Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease.. Metabolism. 147, 155676.
Polyzos, S. A., Mathew H., & Mantzoros C. S. (2015).  Irisin: A true, circulating hormone.. Metabolism. 64(12), 1611-8.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2012).  Sulfated oxysterols as candidates for the treatment of nonalcoholic fatty liver disease.. Metabolism. 61(6), 755-8.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2019).  Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?. Metabolism. 96, iii-v.
Polyzos, S. A., & Margioris A. N. (2018).  Sarcopenic obesity.. Hormones (Athens). 17(3), 321-331.
Polyzos, S. A., Kountouras J., Zavos C., & Tsiaousi E. (2010).  The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease.. Diabetes Obes Metab. 12(5), 365-83.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2014).  Helicobacter pylori infection, insulin resistance and nonalcoholic fatty liver disease.. Med Hypotheses. 82(6), 795.
Polyzos, S. A., Goulas A., & Papaioannidou P. (2023).  Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis. Current Medicinal Chemistry. 30,

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.